Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Community engagement vital in battle against antimicrobial resistance: Wal-yan Centre to establish reference group

The Wal-yan Respiratory Research Centre is seeking expressions of interest from Western Australians to join an Antimicrobial Resistance (AMR) Community Reference Group, to provide vital community perspectives on the research activities into this global health concern. 

Research collaborators

The development of research partnerships is a priority for InterRett, with centres or clinicians with access to large numbers of patients with Rett syndrome.

News & Events

Celebrating our final births

ORIGINS has welcomed its very last baby into the cohort

Nature Play & Grow

Helping families to unlock the mental and physical health benefits of connecting with nature and community through outdoor play - easily, and locally.

Research

Cystic Fibrosis

Cystic fibrosis (CF) is the most common chronic, life-shortening genetic condition affecting young Australians. There is no cure but researchers are working to prevent the onset of lung disease.

News & Events

MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

A The Kids Research Institute Australia spin-off company has received $20 million from the Medical Research Commercialisation Fund to develop a promising new therapy for the treatment of Cystic Fibrosis.

News & Events

My child is wheezing – what should I do?

Almost 50 per cent of preschool children will experience at least one episode of wheeze, a whistling sound produced by the airways during breathing.

Respiratory Research Teams

The Wal-yan Respiratory Research Centre is made up of multi-disciplinary teams that are committed to improving the lives of children and their families living with respiratory disease.

Research

Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children

Invasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.